<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563197</url>
  </required_header>
  <id_info>
    <org_study_id>17607</org_study_id>
    <secondary_id>CIV-15-07-013749</secondary_id>
    <nct_id>NCT02563197</nct_id>
  </id_info>
  <brief_title>Inhalation Flow Rate-study</brief_title>
  <official_title>An Open, Multi-center Study to Measure Inhaled Flow Rates Generated by Non-CF Bronchiectasis Patients for the T-326 Inhaler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study should show feasibility of the device for drug delivery into the lung independently of
      the severity of impaired lung function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to measure inspiratory profiles of patients with non-Cystic fibrosis
      bronchiectasis using the breath activated T-326 Inhaler.

      The following parameters will be derived from the inspiratory profiles:

        -  Peak Inspiratory Flow (PIF, in L/min)

        -  Inspiratory Volume (V, in L)

        -  Inspiratory Time (t, in s).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2015</start_date>
  <completion_date type="Actual">April 29, 2016</completion_date>
  <primary_completion_date type="Actual">February 17, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak inspiratory flow (L/min)</measure>
    <time_frame>Visit 2 (1-14 days after screening visit 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inspiratory volumes (V in L)</measure>
    <time_frame>Visit 2 (1-14 days after screening visit 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory time (t in s)</measure>
    <time_frame>Visit 2 (1-14 days after screening visit 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>T-326</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T-326 Inhaler</intervention_name>
    <description>No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.</description>
    <arm_group_label>T-326</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of non-cystic fibrosis bronchiectasis, confirmed and documented
             by high resolution computed tomography (HRCT) or magnetic resonance tomography (MRT)

          -  Ability to reproducibly perform spirometry according to American Thoracic
             Society/European Respiratory Society criteria

          -  Clinically stable in the opinion of the investigator at the time of the study visit.

          -  Male and female patients ≥ 18 years of age.

        Exclusion Criteria:

          -  Pulmonary exacerbation (as judged by the investigator, based on the clinical condition
             of the subject and taking into account e.g., febrile infection of the lung, relevant
             decrease in Forced expiratory volume in the first second (FEV1) value, increased
             sputum production, sputum purulence, recent hospitalization) at study visit or within
             the preceding six (6) weeks.

          -  History of lung transplant.

          -  Recent significant hemoptysis (≥ 300 mL or requiring blood transfusion) in the
             preceding six (6) weeks before screening.

          -  Established diagnosis of bronchial asthma.

          -  Established diagnosis of cystic fibrosis.

          -  Proof of any relevant medical finding or disease in the last three (3) months which
             might interfere with participation in the study or patient safety (e.g. pneumothorax,
             uncontrolled hypertension, uncontrolled cardiac arrhythmia, myocardial infarction,
             cerebral vascular accident).

          -  A relevant disease that is considered to interfere with the study results is any
             disease that, except for the impairment of lung function, interferes with the
             patient's ability to inhale from the device. For example, COPD per se is usually not
             considered as a reason for patient exclusion, unless coughing or obliteration of the
             upper airways with sputum interferes with the patient's ability to inhale from the
             device.

          -  Relevant surgical history in the last 3 months (e.g., but not limited to abdominal,
             thoracic, ocular or brain surgery).

          -  History or evidence of lung resection, thoracotomy, known aneurysm and severe
             scoliosis.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gauting</city>
        <state>Bayern</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Landsberg</city>
        <state>Bayern</state>
        <zip>86899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neu-Isenburg</city>
        <state>Hessen</state>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Device study</keyword>
  <keyword>Peak inspiratory flow rate</keyword>
  <keyword>Non-cystic fibrosis bronchiectasis</keyword>
  <keyword>T-326 Inhaler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

